Therapeutics: MAP kinase 7 (MAPK7; BMK1; ERK-5); mitogen-activated protein kinase kinase kinase 2 (MAP3K2); WNK lysine deficient protein kinase 1 (WNK1; PPP1R16

Patient sample, mouse and cell culture studies suggest inhibiting MAPK7 or the MAPK7 pathway components MAP3K2 and WNK1 could help treat prostate adenocarcinoma cancer harboring gain-of-function FOXF1...